Last reviewed · How we verify
AB011 Injection
At a glance
| Generic name | AB011 Injection |
|---|---|
| Also known as | recombinant humanized anti-Claudin 18.2 monoclonal antibody injection, recombinant humanized anti-CLDN 18.2 monoclonal antibody injection |
| Sponsor | CARsgen Therapeutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |